3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
42
Observational
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
1
Lung Neoplasms
1
Liver Neoplasms
1
Glioma
1
Glioblastoma
1
Breast Cancer Organoids
1
Advanced Gastric Cancer
1
Interventions
Sorafenib
20
lenvatinib
18
Hepatectomy
17
Blood Specimen Collection
12
Immune Checkpoint Inhibitors
11
Liver Transplantation
9
atezolizumab
8
Surgical Procedures, Operative
7
Radiofrequency Ablation
7
Observation
7
Bevacizumab
6
regorafenib
5
gadolinium ethoxybenzyl DTPA
5
sintilimab
4
donafenib
4
camrelizumab
4
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
tislelizumab
3
spartalizumab
3
Polymerase Chain Reaction
3
Neoadjuvant Therapy
3
Mass Spectrometry
3
Immunohistochemistry
3
Doxorubicin
3
Angiogenesis Inhibitors
3
toripalimab
2
pembrolizumab
2
entecavir
2
apatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Hepatocellular
×
apatinib
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled
NCT05717738
2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
300 enrolled